VivoSeq
Cardiovascular

Heart Disease

139

Pipeline Programs↗

20

Active Trials↗

49

Companies Involved↗

Heart Disease is a highly competitive landscape with 139 programs across 49 companies. The most active players are New Haven Pharmaceuticals, Inc., McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Roche. 41 therapies are approved with 30 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

75/100

Pipeline Velocity

32/100

Mech. Concentration

6/100

Completion Rate

89/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

N

New Haven Pharmaceuticals, Inc.

1 program

Phase 1M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 1Roche logo

Roche

2 programs

Phase 2GSK logo

GSK

2 programs

Phase 2H

Help Therapeutics

2 programs

Phase 2R

Rohto Pharmaceutical Co., Ltd.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical29

Amiodarone

Wyeth-Lederle Vaccines

Deferiprone

Chiesi Farmaceutici S.p.A.

Statin

Bristol-Myers Squibb

Pravastatin

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Losartan

Organon and Co

Phase 18

Dexmedetomidine

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Nacl

Bayer

Allorx

The Foundation for Orthopaedics and Regenerative Medicine

Durlaza™

New Haven Pharmaceuticals, Inc.

L-Citrulline Malate

Masih Daneshvari Hospital

Phase 231

Atenolol

Twinpig Biolab, Inc.

Azithromycin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Telmisartan

Boehringer Ingelheim

Mesenchymal Stem Cell

Rohto Pharmaceutical Co., Ltd.

Empagliflozin

Boehringer Ingelheim

Phase 330

Norepinephrine

General Hospital of Ningxia Medical University

Semaglutide

Novo Nordisk

Medroxyprogesterone Acetate

Eli Lilly

Estrogen

Eli Lilly

Udenafil

Mezzion Pharma Co. Ltd

Approved41

Propofol

Fresenius Kabi Oncology Ltd.

Metformin

EMD Serono

Magnesium Sulfate

Fresenius Kabi Oncology Ltd.

Warfarin

Abbott

Captopril

Standard Chem. & Pharm. Co., Ltd.

Analysis

Modality Breakdown

95%

Small molecule

154 of 162 classified programs — the dominant modality here.

5%ALL OTHERSCell therapy32%Peptide21%Monoclonal antibody1<1%RNA therapy1<1%Vaccine1<1%

Small molecule leads; the ring shows all 162 classified programs, each share of the total. Modality classified for 100% of 167 pipeline programs.

Analysis

Trial Status

144

clinical trials

Completed81 · 56%
Unknown status32 · 22%
Recruiting10 · 7%
Terminated8 · 6%
Not yet recruiting6 · 4%
Active, not recruiting3 · 2%
Other4 · 3%

Clinical Trials

Trial Activity

144 trials

Effect of Individualized Exercise in Elderly Patients With Coronary Heart Disease
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·N/A·NCT06588231·200 enrolled
Pre-trial of Clinical Trial of Traditional Chinese Medicine Treatment for Elderly Patients With Coronary Heart Disease Who Are Still Symptomatic After Optimal Medical Treatment
Recruiting·CChina National Center for Cardiovascular Diseases·Phase 4·NCT07041359·120 enrolled
Effect of Xuesaitong Soft Capsules on Major Risk Factors in Patients With Coronary Heart Disease
Recruiting·CChina National Center for Cardiovascular Diseases·Phase 4·NCT06425120·240 enrolled
COLchicine and Thiamine in Heart Failure Due to Ischemic Heart Disease
Recruiting·HHamilton Health Sciences Corporation·Phase 3·NCT05873881·2,500 enrolled
Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
Recruiting·SSPH Qingdao Growful Pharmacetical Co.,Ltd·Phase 4·NCT07110415·2,708 enrolled
"The Effect of The Combination Therapy of Statin and SGLT2i in The Treatment of Ischemic Heart Disease"
Recruiting·FFayoum University·N/A·NCT06520891·90 enrolled
A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease
Recruiting·—·Phase 1/2·NCT07493603·30 enrolled
CATAMARAN - Neonatal Cohort : Characterization and Support of Neurodevelopmental Disorders Associated With Congenital Cardiac malfoRmations - Neonatal
Recruiting·NNantes University Hospital·N/A·NCT06690151·450 enrolled
Construction of a Prospective Cohort Database for the Perioperative Period of Cardiac Surgery
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT07662317·10,000 enrolled
PHenotype-based RApid SEquencing of Guideline-directed Medical Therapy for Heart Failure With Reduced Ejection Fraction (PHRASE-HF): A Multicentre, Prospective, Non-interventional Study to Examine Outcomes of Rapid In-hospital Implementation of GDMT and Its Translation From Discharge Into Routine Care
Recruiting·AstraZeneca logoAstraZeneca·N/A·NCT06675552·438 enrolled
Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 3·NCT04810091·79 enrolled
VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease
Active, not recruiting·—·Phase 4·NCT06249165·130 enrolled
The Influence of Probiotics on Metabolome and Heart Rate Variability in Heart Failure of Structure Heart Disease
Active, not recruiting·—·N/A·NCT06872320·120 enrolled
Continuity of Care Between Primary Care Cardiology and Specialty Services for Patients With Chronic Ischemic Heart Disease
Not yet recruiting·—·Phase 4·NCT06421363·50 enrolled
Exploratory Study of ADR-002K for Heart Failure Patients With Ischemic Heart Disease Who Undergo CABG
Not yet recruiting·RRohto Pharmaceutical Co., Ltd.·Phase 2·NCT07192211·50 enrolled
Page 1 of 10

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)